Published in J Oncol Pract on May 01, 2012
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med (1991) 6.33
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol (2009) 4.56
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol (2006) 4.19
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer (2005) 2.25
Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer (2010) 2.07
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis (2005) 1.58
Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol (2006) 1.24
Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer (2010) 1.15
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol (2010) 1.09
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. J Clin Oncol (2001) 0.88
A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (2006) 0.82
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer (2003) 0.82
Does surgery induce angiogenesis in breast cancer? Indirect evidence from relapse pattern and mammography paradox. Int J Surg (2005) 6.80
Sheath of guidewire of ureteric stent as an aid to extubation in difficult pediatric airway. Paediatr Anaesth (2008) 2.58
Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening. J Clin Oncol (2004) 2.28
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol (2005) 2.10
Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol (2007) 1.93
Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther (2003) 1.64
Examining racial disparities in colorectal cancer care. J Psychosoc Oncol (2009) 1.42
A randomized controlled trial of multiple tailored messages for smoking cessation among callers to the cancer information service. J Health Commun (2005) 1.35
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther (2006) 1.15
Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem (2009) 1.14
Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience. Cancer (2005) 1.13
Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res (2009) 1.12
The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int (2009) 1.11
Global breast cancer seasonality. Breast Cancer Res Treat (2010) 1.09
Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer (2007) 1.08
Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat (2005) 1.08
Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. Int J Exp Pathol (2006) 1.07
Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiol Int (2002) 1.05
Multiple tailored messages are effective in increasing fruit and vegetable consumption among callers to the Cancer Information Service. J Health Commun (2005) 1.05
Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res (2008) 1.05
Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat (2008) 1.03
Using a central venous pressure guidewire and suction catheter to facilitate oral to nasal tracheal tube change in a child with a difficult airway. Anesth Analg (2009) 1.00
Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res (2004) 1.00
Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem (2013) 0.97
Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther (2005) 0.96
Clock genes and cancer. Integr Cancer Ther (2009) 0.96
Re: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst (2004) 0.95
A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer (2010) 0.93
Prohibitin as an oxidative stress biomarker in the eye. Int J Biol Macromol (2010) 0.91
Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psychooncology (2010) 0.91
Circadian disruption, Per3, and human cytokine secretion. Integr Cancer Ther (2009) 0.90
Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem (2008) 0.90
Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer (2009) 0.89
Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther (2009) 0.89
The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer (2011) 0.88
Cleavage of the retinal pigment epithelium-specific protein RPE65 under oxidative stress. Int J Biol Macromol (2010) 0.88
Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat (2002) 0.86
The NCI's Cancer Information Service's Research Continuum Framework: integrating research into cancer education practice (1999-2004). J Cancer Educ (2007) 0.85
Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 0.85
Melatonin reprogrammes proteomic profile in light-exposed retina in vivo. Int J Biol Macromol (2010) 0.84
Sex cycle modulates cancer growth. Breast Cancer Res Treat (2005) 0.83
Authors respond to controversy surrounding breast cancer study. Int J Surg (2005) 0.82
Enhanced surgery-induced angiogenesis among premenopausal women might partially explain excess breast cancer mortality of blacks compared to whites: an hypothesis. Int J Surg (2007) 0.81
Seasonal modulation of post-resection breast cancer metastasis. Breast Cancer Res Treat (2007) 0.78
Imaging multidimensional therapeutically relevant circadian relationships. Int J Biomed Imaging (2009) 0.78
The flavonoid derivative 2-(4' Benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Aβ42-induced neurodegeneration in transgenic Drosophila: insights from in silico and in vivo studies. Neurotox Res (2014) 0.78
Allometric scaling law questions the traditional mechanical model for axillary lymph node involvement in breast cancer. J Clin Oncol (2006) 0.77
Capnography guided retrograde intubation with the aid of sheath of fogarty embolectomy catheter. Paediatr Anaesth (2008) 0.77
Efficient identification of low-income Asian American women at high risk for hepatitis B. J Health Care Poor Underserved (2013) 0.77
Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst (2002) 0.77
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature. Arch Oncol (2010) 0.76
Circadian transcription profile of mouse breast cancer under light-dark and dark-dark conditions. Cancer Genomics Proteomics (2010) 0.76
Screening and breast cancer. N Engl J Med (2006) 0.75
Tube migration during laparoscopic gynecological surgery. J Anaesthesiol Clin Pharmacol (2010) 0.75
Translational health research: perspectives from health education specialists. Clin Transl Med (2012) 0.75
Androgen suppression and irradiation for locally advanced prostate cancer. Lancet (2002) 0.75
Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005. Breast Cancer Res Treat (2006) 0.75
Comment to Jatoi et al. report. Breast Cancer Res Treat (2005) 0.75
The role of the APRN in addressing prescription drug abuse in Tennessee. Tenn Nurse (2014) 0.75
Correspondence. J Natl Compr Canc Netw (2012) 0.75
Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care (2012) 0.75
Reluctant reflections. An oncologist's take on how physician and patient burnout might be prevented. Minn Med (2015) 0.75
Discovery of candidate genes and pathways that may help explain fertility cycle stage dependent post-resection breast cancer outcome. Breast Cancer Res Treat (2009) 0.75